ライフサイエンスコーパス: ovarian adenocarcinoma

1 mesothelioma, pancreatic adenocarcinoma, and ovarian adenocarcinoma.

2 ain, melanoma, invasive ductal carcinoma and ovarian adenocarcinoma.

3 bservation made in a wide selection of human ovarian adenocarcinomas.

4 ogical markers for distinguishing colon from ovarian adenocarcinomas.

5 deletions is also observed in prostatic and ovarian adenocarcinomas.

6 potential (LMP) and 66 classified as primary ovarian adenocarcinomas].

7 d frequent loss of p27 expression in primary ovarian adenocarcinomas (33%), with respect to LMP tumor

8 isition of cisplatin resistance in the human ovarian adenocarcinoma A2780 cell line.

9 nes aberrantly expressed in serous papillary ovarian adenocarcinoma and may be useful for the identif

10 (O/E, 1.29; 95% CI, 1.06-1.56) and mucinous ovarian adenocarcinoma and rectal cancer (OE/E, 1.95; 95

11 s, has a broad expression range in colon and ovarian adenocarcinomas, and may behave as a biomarker f

12 adenocarcinoma; SKVLB a multidrug resistant ovarian adenocarcinoma; and HT-29, a colon carcinoma).

13 Ovarian adenocarcinomas are shown to be an excellent mod

14 (25 of 32) of breast and 44% (76 of 171) of ovarian adenocarcinoma as assessed by in situ hybridizat

15 Parental cells of the human ovarian adenocarcinoma cell line 2008 expressed hMLH1 wh

16 d (ATRA) treatment of the retinoid-sensitive ovarian adenocarcinoma cell line CAOV3, but not the reti

17 The human ovarian adenocarcinoma cell line HEY showed a similar re

18 coprotein (P-gp) gene silencing in the human ovarian adenocarcinoma cell line, NCI-ADR/Res (NAR), ove

19 RI shedding was confirmed in the SW626 human ovarian adenocarcinoma cell line.

20 mber of human tumor cells, including several ovarian adenocarcinoma cell lines.

21 physiological setting, TGF-beta insensitive ovarian adenocarcinoma cells (HEY) have a very low GULP

22 MDR ovarian adenocarcinoma cells (NIH:OVCAR-3) also containe

23 in two living human tumor cell lines: Caov-3 ovarian adenocarcinoma cells and A-498 kidney carcinoma

24 ention of 8 and 13 in ip xenografts of human ovarian adenocarcinoma cells NIH:OVCAR-3, which overexpr

25 nomic dsDNA breaks (DSBs) were identified in ovarian adenocarcinoma cells using immunodetection of ga

26 endometrial carcinoma cells), OVCAR-3 (human ovarian adenocarcinoma cells), EM42 (human endometrial e

27 a cells, COS-1 cells, HeLa cells, or SK-OV-3 ovarian adenocarcinoma cells, all of which do not expres

28 FGF16 stimulates the proliferation of human ovarian adenocarcinoma cells, SKOV-3 and OAW-42.

29 number of human cancer cell lines including ovarian adenocarcinoma cells.

30 that rhuCD40L inhibits the growth of several ovarian adenocarcinomas derived from surgical specimens

31 pies, including hepatocellular carcinoma and ovarian adenocarcinoma, Gadd45b inhibition in myeloid ce

32 Human ovarian adenocarcinoma (HTB 77 IP3) cells were grown in

33 of peritoneal endometriosis and endometrioid ovarian adenocarcinoma in mice, both based on the activa

34 cy in the United States, and advanced serous ovarian adenocarcinoma is responsible for most ovarian c

35 ogical association between endometriosis and ovarian adenocarcinoma may be attributable to shared gen

36 ung cancer (H1299), osteosarcoma (143B), and ovarian adenocarcinoma (OVCAR8).

37 ta indicate that gene expression patterns in ovarian adenocarcinomas reflect both morphological featu

38 ethods: Human pleural mesothelioma (I45) and ovarian adenocarcinoma (SKOV3) cell lines were engineere

39 different human tumor cell lines (SKOV3, an ovarian adenocarcinoma; SKVLB a multidrug resistant ovar

40 invasive and widely metastatic endometrioid ovarian adenocarcinomas with complete penetrance and a d

41 de, which caused tumor regression in a human ovarian adenocarcinoma xenograft model with on-pathway b

42 les were quantified in 42 mice bearing human ovarian adenocarcinoma xenograft tumors by use of a high

43 rin expression on endothelial cells of human ovarian adenocarcinoma xenograft tumors.

44 For ovarian adenocarcinoma xenografts, SK-OV-3, dEpoB (i.p.)

45 ibution studies in mice bearing OVCAR3 human ovarian adenocarcinoma xenografts.